Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5G-PEARL: paxalisib plus temozolomide in biomarker-selected glioblastoma
ISRCTN88772403Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Feb 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of paxalisib and temozolomide in glioblastoma (GBM) (2 arms), sponsored by The Institute of Cancer Research. Started Feb 2026; status: recruiting.
02
Drugs
paxalisibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ISRCTN88772403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88772403.